Login with your social media account

Login with Facebook


The latest answers in cancer immunotherapy


Atezolizumab Receives FDA Approval for Bladder Cancer

05/19/2016 | Cancer Research Institute
It becomes the first FDA-approved checkpoint blockade immunotherapy for bladder cancer.

read more »


Immunotherapy FDA Approved for Hodgkin Lymphoma

05/17/2016 | Cancer Research Institute
Nivolumab becomes first checkpoint immunotherapy approved for lymphoma.

read more »


What If Your Immune System Could Be Taught to Kill Cancer?

03/28/2016 | Time
A look at immunotherapy clinical trials, and the patients who participate in them.

read more »


Drugs That Ramp Up the Immune System against Tumor Cells are Revolutionizing Cancer Treatment

03/21/2016 | Scientific American
Enhancing the body's own immune system is leading to promising results in the battle against malignancy.

read more »


Jimmy Carter Says He No Longer Needs Cancer Drug Treatment

03/07/2016 | ABC News
Jimmy Carter announced that he no longer needs treatment for cancer, less than seven months after revealing he had been diagnosed with melanoma that spread to his brain.

read more »


The Most Promising Cancer Therapy in Decades Is About to Get Better

03/03/2016 | The Atlantic
Tumors contain the seeds of their own destruction. We just need to work out how to activate them.

read more »


CRI Meets with the Vice President's Staff on Moonshot

02/26/2016 | Cancer Research Institute
CRI and Vice President Biden’s Moonshot Initiative collaborate for the advancement of cancer immunotherapy research.

read more »


ASCO Names Cancer Immunotherapy “Advance of the Year”

02/05/2016 | Cancer Research Institute
ASCO President: “No recent cancer advance has been more transformative than immunotherapy.”

read more »


Obama proposes $1 billion for cancer research

02/01/2016 | USA Today
The White House is putting a dollar sign in front of its ambitious effort to cure cancer, announcing $1 billion in funding over the next two years.

read more »


FDA Approves Frontline Opdivo for BRAF-Mutant Melanoma

01/25/2016 | Cure
The FDA has expanded the frontline melanoma indications for Opdivo (nivolumab) as a single agent and in combination with Yervoy (ipilimumab) to include patients with BRAF V600 mutations.

read more »


Featured stories

The former president will receive a drug called pembrolizumab, a PD-1-blocking antibody.
read more »

Rocket Fuel

join us

Join the ImmunoCommunity to access an important resource for all things related to cancer immunotherapy. Connect with others who have shared experiences and learn about new treatment options.

join us »

donate now

To continue to find the answers to cancer, it takes funding for research. Donate to the Cancer Research Institute today to help us continue to search for answers.

donate »